Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of Posdinemab in Healthy and AD Subjects
NCT03375697Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2017
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, randomised, double-blind trial of posidinemab in Alzheimer's disease (AD) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Number of Subjects With Adverse Events as a Measure of Safety and Tolerability. Started Dec 2017; status: completed.
02
Drugs
posidinemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03375697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03375697.